Received Aug 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (IMOVAX) | SANOFI PASTEUR | 1 | Y1A8CP1 | OT |
started a two-dose pre-exposure series but never received her second dose with no reported ae; Initial information received on 01-Aug-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 53-year-old female patient who started a two-dose pre-exposure series of Rabies (HDC) vaccine [IMOVAX Rabies] but never received her second dose with no reported ae (adverse event). The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 25-Jun-2025, the patient received a first dose of 0.5ml of suspect Rabies (HDC) vaccine Powder and solvent for suspension for injection (lot Y1A8CP1, standard strength, frequency once, and expiry date-28-Feb-2025) via intramuscular route in unknown administration site for Immunization and was to receive two-doses of pre-exposure series but never received her second dose with no reported ae (routine immunisation schedule not administered). Reportedly-Patient missed the second dose they wanted to know if they can get the second dose or they need to restart. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.